Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutic... (ttp://www.immunosyn.com target

HOME >> MEDICINE >> TECHNOLOGY

Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019

Date:11/28/2007

ttp://www.immunosyn.com" target="_new">http://www.immunosyn.com).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Immunosyn Corporation Releases SF-1019 Study Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

Post Your Comments:

(Date:8/19/2008)...., Aug. 19 /- Particle Sciences Inc. ... polymers) development and,pilot production capabi...rusion and injection molding line. The core of the...ding extruder and Nissei 20T injection,molder, ena...lymeric,devices. This addition gives Particle Scie...

(Date:8/19/2008)...nn., Aug. 19 /- VION,PHARMA...y that it had,entered into an agreement with the D...y Oncology (the "HOVON") to conduct a clinical tri...h standard remission-induction,therapy in patients...enous,leukemia (AML) and high-risk myelodysplasia ...

(Date:8/18/2008)...g. 18 /- The next time you consider p...t might be worth counting sheep,instead. A senior ... San,Diego, Calif. has found evidence that taking ...skin cancer., Daniel F. Kripke, M.D.,s article, b...g pills and cancer, has just been published in the...

(Date:8/18/2008)...rael, August 18 /- Oramed,P....oramed.com ), a developer,of oral delivery system...en,Label Study to Assess the Safety, Pharmacokinet...sulin Formulations in Healthy,Subjects," has been ...l,Meeting of the European Association for the Stud...

Breaking Medicine Technology:Particle Sciences Expands Its Combination Product Capabilities 2 Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 2 Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 3 Prescription Sleeping Pill Use Tied to Cancer 2 Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2 Addition of INTEGRILIN 28R 29 28Eptifibatide 29 to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Co 760 1 Addition of INTEGRILIN 28R 29 28Eptifibatide 29 to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Co 760 2 Addition of INTEGRILIN 28R 29 28Eptifibatide 29 to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Co 760 3 Addition of INTEGRILIN 28R 29 28Eptifibatide 29 to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Co 760 4 Addition of INTEGRILIN 28R 29 28Eptifibatide 29 to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Co 760 5 For migrating sparrows kids have a compass but adults have the map 1116 1 For migrating sparrows kids have a compass but adults have the map 1116 2 Breastfeeding boost IQ in infants with helpful genetic variant 1115 1 Breastfeeding boost IQ in infants with helpful genetic variant 1115 2 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation 5569 1 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation 5569 2

[0] Particle Sciences Expands Its Combination Product Capabilities [0] Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy [1] Prescription Sleeping Pill Use Tied to Cancer [0] Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)

...tudy results will be presented at the American Col...TO, Calif., March 06, 2007 /PRNewswire-FirstCall/ ...nalysis of unblinded,data from the MERLIN TIMI-36 ...nd in death or arrhythmias in patients on ranolazi...dpoint. , In accordance with the company,s special...

...port Ability of Higher Doses to Further Reduce Ant...8, 2007 /PRNewswire-FirstCall/ -- La Jolla,Pharmac...ntibody,results from its ongoing double-blind, pla...t(R) (abetimus sodium), its drug,candidate for sys...yses of interim antibody data indicate that patien...

Other Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2 CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3 La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2 La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3 La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4 La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5 La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6 La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 7

CV Therapeutics Announces Topline MERLIN TIMI-36 Results La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...There is just single mental health bed in South Au...dly the country’s worst rate. The national average...unding to NGOs which cater // to mental health is ...mber of mental health disorders in South Australia...

...In Canada questions have arisen about the best app...re. The evidences point out to be that more people...facilities. // In Britain the London’s public Qu...ample financial difficulty due to public-private p...

...Natural selection is reported to have been respons... the course of the past 50,000 years. The tendency...ate fields can also be traced // to this natural s...r genes that have recently been changed by natural...

...The French are reluctant to place their orders for...u. However, the dreaded disease has not stopped t... Christmas turkeys // this year, say industry sour...such as restaurants and retailers are cautious in ...

Other Medicine News:Health News:DNA Underwent Changes Due To Culture 2 Health News:Christmas turkey? Anyone? 2

Mental Health Services In Poor Shape Evidences that Better Health Care Facility is Offered By Public Hospitals.DNA Underwent Changes Due To Culture Christmas turkey? Anyone?

VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula.

Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port

Infusion Cannula, 4.0mm.

Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°.

Medicine Products:

VISCO SHIELD Viscoelastic Universal I/A handpiece - Stainless steel (Round Handle with Straight Tip)Infusion Cannula 4.0mm Subretinal Fluid Cannula Curved

Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutic...(ttp://www.immunosyn.com target _new htt...),Health